Trial reportEuropean journal of applied physiology2017
Beta
Trial report in European journal of applied physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Interventions associated with brown adipose tissue activation and the impact on energy expenditure and weight loss: A systematic review.Frontiers in endocrinology · 2022Pooled it
- Prolonged β2-agonist treatment enhances muscle-specific glucose uptake in individuals with overweight and obesity: a randomized placebo-controlled trial.Nature communications · 2026Trial
- Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial.Nature communications · 2023Trial
- BetaScandinavian journal of medicine & science in sports · 2022Trial
- Effects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial.Sports medicine (Auckland, N.Z.) · 2026Article
- Resting and Physical Activity Energy Expenditure Across an Altitudinal Gradient: An Adjusted Analysis.Oxygen (Basel, Switzerland) · 2026Article
- A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism.JCI insight · 2026Article
- BetaDrug testing and analysis · 2025Article
- The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis.Molecular metabolism · 2024Article
- Paediatric asthma and non-allergic comorbidities: A review of current risk and proposed mechanisms.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Review
- Dietary supplements for lipedema.Journal of preventive medicine and hygiene · 2022Review
- The involvement of the adrenergic nervous system in activating human brown adipose tissue and browning.Hormones (Athens, Greece) · 2022Review
- Muscle hypertrophic effect of inhaled betaThe Journal of physiology · 2022Article
- Resting Energy Expenditure Is Elevated in Asthma.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeβ
methodsNineteen males were included in the study of which 14 completed. Subjects were 31.6 (±3.5) years [mean (±95% CI)] and had a fat percentage of 22.7 (±2.1)%. On separate days, subjects received either placebo or inhaled racemic (rac-) formoterol (2 × 27 µg). After an overnight fast, energy expenditure and substrate oxidation were estimated by indirect calorimetry at rest and during submaximal exercise. Plasma (R,R)- and (S,S)-formoterol enantiomer levels were measured by ultra-performance liquid chromatograph-mass spectrometry.
resultsAt rest, energy expenditure and fat oxidation were 12% (P ≤ 0.001) and 38% (P = 0.006) higher for rac-formoterol than placebo. Systemic (R,R):(S,S) formoterol ratio was correlated with change in energy expenditure at rest in response to rac-formoterol (r = 0.63, P = 0.028), whereas no association was observed between fat percentage and rac-formoterol-induced change in energy expenditure. During exercise, energy expenditure was not different between treatments, although carbohydrate oxidation was 15% higher (P = 0.021) for rac-formoterol than placebo. Rac-formoterol-induced shift in substrate choice from rest to exercise was related to plasma ln-rac-formoterol concentrations (r = 0.75, P = 0.005).
conclusionSelective β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.